ABSTRACT

Cancer-associated thrombosis (CT), especially venous thromboembolism (VTE), is a common occurrence with several factors contributing to a wide diversity in thrombosis risk. The association between ABO blood groups and the risk for CT has been examined in various studies, with non-O blood type associated with an increased thrombosis risk; however, these studies have reported varying results with recognized limitations. ABO blood groups are known to be implicated in hemostasis, in an association mediated through von Willebrand factor (VWF). In this narrative review, we aim to summarize the current knowledge surrounding the role of ABO blood groups in VTE, with a particular focus on the role of VWF and other contributing risk factors on VTE occurrence. We found evidence from literature for the impact of ABO blood groups in determining the risk of VTE in healthy populations, with a limited number of studies examining this effect in cancer patients. Additionally, research on the impact of ABO on different cancer types lacks rigor, particularly in regard to other risk factors. Overall, most studies showed strong association of increased risk of VTE amongst cancer patients with non-O blood groups and increased VWF levels. This association was weaker in a few studies. Further research is needed before a solid conclusion can be made about the ABO or ABO-VWF-mediated hypercoagulability and VTE risk in various cancers. These studies will help determine if ABO typing can be an added biomarker to improve VTE risk assessment models in cancer patients.

PMID:37751774 | DOI:10.1055/s-0043-1775568

16:20

Photo

Not included, change data exporting settings to download.

1200×1200, 39.0 KB

16:20

Photo

Not included, change data exporting settings to download.

1200×1200, 39.0 KB

16:20

Photo

Not included, change data exporting settings to download.

1200×1200, 39.0 KB

16:20

Photo

Not included, change data exporting settings to download.

1200×1200, 39.0 KB

16:20

In reply to this message

PubMed articles on: Cancer & VTE/PE

Early identification of lung cancer patients with venous thromboembolism: development and validation of a risk prediction model

Thromb J. 2023 Sep 14;21(1):95. doi: 10.1186/s12959-023-00544-w.

ABSTRACT

INTRODUCTION: Venous thromboembolism(VTE) is a leading cause of death in patients with lung cancer. Furthermore, hospitalization of patients with advanced lung cancer for VTE treatment represents a major economic burden on the national public health resources. Therefore, we performed this prospective study to identify clinical biomarkers for the early identification of VTE in lung cancer patients.

METHODS: This prospective study enrolled 158 patients with confirmed lung cancer, including 27 who were diagnosed with VTE within six months of the follow-up after lung cancer diagnosis. Multivariate logistic regression analysis was used to evaluate the diagnostic performancese of all the relevant clinical features and laboratory indicators in identifying lung cancer patients with a higher risk of VTE. A novel risk prediction model was constructed consisting of five clinical variables with the best diagnostic performances and was validated using the receiver operation characteristic(ROC) curves. The diagnostic performances of the new risk prediction model was also compared with the Khorana risk score (KRS) and the Padua risk score (PRS).

RESULTS: The VTE group of lung cancer patients (n = 27) showed significantly higher serum levels of fibrin degradation products (FDP), D-dimer, thrombomodulin (TM), thrombin-antithrombin-complex (TAT), α2-plasmin inhibitor-plasmin Complex (PIC), and tissue plasminogen activator-plasminogen activator inhibitor complex (t-PAIC) compared to those in the non-VTE group (n = 131). ROC curve analyses showed that the diagnostic efficacy of the new VTE risk prediction model with TM ≥ 9.75 TU/ml, TAT ≥ 2.25ng/ml, t-PAIC ≥ 7.35ng/ml, history of VTE, and ECOG PS score ≥ 2 was superior than the KRS and the PRS in the early identification of lung cancer patients with a higher risk of VTE.

CONCLUSIONS: The new risk prediction model showed significantly high diagnostic efficacy in the early identification of lung cancer patients with a high risk of VTE. The diagnostic efficacy of the new risk prediction model was higher than the KRS and the PRS in this cohort of lung cancer patients.

PMID:37710256 | PMC:PMC10500728 | DOI:10.1186/s12959-023-00544-w

16:20

Photo

Not included, change data exporting settings to download.

1200×1200, 39.0 KB

16:20

Photo

Not included, change data exporting settings to download.

1200×1200, 39.0 KB

16:20

Photo

Not included, change data exporting settings to download.

1200×1200, 39.0 KB

16:20

Photo

Not included, change data exporting settings to download.

1200×1200, 39.0 KB

16:20

In reply to this message

PubMed articles on: Cancer & VTE/PE

Acute myocardial infarction due to coronary embolism caused by a metastatic mass from lung cancer

BMC Cardiovasc Disord. 2023 Sep 15;23(1):461. doi: 10.1186/s12872-023-03505-3.